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Abstract 
The objective of this study was to compare immunological responses and lymphoid depletion in young, 
colostrum deprived calves following administration of vaccines containing modified-live bovine viral 
diarrhea virus (BVDV). A group of calves exposed to a typical virulence non-cytopathic (ncp) BVDV-2 field 
strain (ncp exposed) was included to compare responses of calves receiving vaccine to responses 
generated against a field strain (mimicking a natural infection). A negative control group administered a 
placebo was used in all comparisons. All vaccines used in the study were administered per manufacturer 
recommendations while ncp BVDV exposed calves received 5 ml intranasally (2.5 ml/nare; 4.2 × 106 
TCID50/ml) of the BVDV-2 field strain. Samples collected at each time point included nasal swabs for 
virus detection, blood samples for complete blood counts and detection of viremia, PBMCs for flow 
cytometric analysis, serum for virus neutralization titers, and thymus tissue at necropsy for evaluation of 
lymphoid depletion. A measurable neutralizing BVDV titer was observed for all treatment groups 
excluding the control animals, which remained negative during the study period. Virus shedding was only 
detected from the ncp vaccinated and ncp exposed calves. A decline from baseline was observed for 
peripheral lymphocyte and CD4+ cells for the groups receiving the adjuvanted cytopathic (cp) vaccine, the 
double deleted genetically modified (ddGM) vaccine, the ncp vaccine and ncp exposed calves, but not for 
the control group or groups receiving cp vaccines. Thymus depletion was observed for the ncp vaccine 
and ncp exposed calves and to a lesser extent for the ddGM vaccine calves. Collectively, these data 
suggest that the virus biotype, method of attenuation, presentation, and use of adjuvant will influence 
vaccine impacts on lymphoid tissues and the immune response. As such, multiple variables should be 
considered when determining costs and benefits of vaccination. 
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a b s t r a c t
The objective of this study was to compare immunological responses and lymphoid depletion in young,
colostrum deprived calves following administration of vaccines containing modified-live bovine viral
diarrhea virus (BVDV). A group of calves exposed to a typical virulence non-cytopathic (ncp) BVDV-2 field
strain (ncp exposed) was included to compare responses of calves receiving vaccine to responses gener-
ated against a field strain (mimicking a natural infection). A negative control group administered a pla-
cebo was used in all comparisons. All vaccines used in the study were administered per manufacturer
recommendations while ncp BVDV exposed calves received 5 ml intranasally (2.5 ml/nare; 4.2  106
TCID50/ml) of the BVDV-2 field strain. Samples collected at each time point included nasal swabs for virus
detection, blood samples for complete blood counts and detection of viremia, PBMCs for flow cytometric
analysis, serum for virus neutralization titers, and thymus tissue at necropsy for evaluation of lymphoid
depletion. A measurable neutralizing BVDV titer was observed for all treatment groups excluding the
control animals, which remained negative during the study period. Virus shedding was only detected
from the ncp vaccinated and ncp exposed calves. A decline from baseline was observed for peripheral
lymphocyte and CD4+ cells for the groups receiving the adjuvanted cytopathic (cp) vaccine, the double
deleted genetically modified (ddGM) vaccine, the ncp vaccine and ncp exposed calves, but not for the
control group or groups receiving cp vaccines. Thymus depletion was observed for the ncp vaccine and
ncp exposed calves and to a lesser extent for the ddGM vaccine calves. Collectively, these data suggest
that the virus biotype, method of attenuation, presentation, and use of adjuvant will influence vaccine
impacts on lymphoid tissues and the immune response. As such, multiple variables should be considered
when determining costs and benefits of vaccination.
Published by Elsevier Ltd.
1. Introduction
Ruminant pestiviruses are globally-distributed pathogens that
include bovine viral diarrhea virus-1 (BVDV-1) and BVDV-2 that
are grouped in two different species, Pestivirus A and B, respec-
tively. BVDV-1 and 2 are comprised of multiple subgenotypes that
belong to the genus Pestivirus, family Flaviviridae. BVDV infections
result in a wide range of clinical manifestations that can affect the
reproductive, digestive and respiratory systems, with the impact
ranging from mild to severe [1,2]. The form of clinical disease
observed is dependent on the agent, host, and environmental fac-
tors, as well as the interaction of these factors. BVDV can exist as
two biotypes, cytopathic (cp) or non-cytopathic (ncp), as defined
by their effect in cultured cells. Similarities and differences can
be observed between the two biotypes with regard to immune eva-
sion mechanisms [3]. The most notable difference is impact of
infection on pregnant animals. The ncp biotype is most frequently
detected in the field and infection with ncp biotype in pregnant
animals may result in embryonic death, resorption, and stillbirth,
https://doi.org/10.1016/j.vaccine.2020.09.046
0264-410X/Published by Elsevier Ltd.
⇑ Corresponding author.
E-mail address: shollie.falkenberg@usda.gov (S.M. Falkenberg).
Vaccine xxx (xxxx) xxx
Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vacc ine
Please cite this article as: S. M. Falkenberg, R. P. Dassanayake, M. V. Palmer et al., Changes in circulating lymphocytes and lymphoid tissue associated with
vaccination of colostrum deprived calves, Vaccine, https://doi.org/10.1016/j.vaccine.2020.09.046
or the birth of persistently infected (PI) calves. Regardless of bio-
type, a hallmark characteristic associated with BVDV infection is
immunosuppression [4,5]. The changes associated with the
immunosuppressive actions include, but are not limited to, a
decrease in circulating lymphocytes, depletion of lymphoid tissue,
and inhibition of metabolic activities of stimulated lymphocytes.
Variation in the severity of immunosuppression has been reported
between BVDV isolates that differ in virulence [6], as well as bio-
type [7]. Some immunosuppressive effects of BVDV are thought
to be properties specific to each respective isolate and may not
necessarily be representative of biotype or genotype [7,8].
The composition of currently available modified live viral (MLV)
BVDV vaccines in the US, include cp BVDV isolates andmay contain
adjuvants. While currently available MLV vaccines contain cp vac-
cine strains, the strains used in each vaccine can differ. Further-
more, previously available BVDV MLV vaccines have contained
ncp BVDV in their composition. In addition, double-deleted, genet-
ically modified (ddGM) attenuated BVDV isolates have been
licensed in other countries. Therefore, BVDV MLV vaccine compo-
sition can vary in biotype, strain, adjuvant, and attenuation
method. Each of these variables could affect the immune response
and potentially alter the degree of immune suppression that is
observed with each respective BVDV MLV vaccine.
In 2014, the USDA Center for Veterinary Biologics issued a
notice (No. 14-06) that outlined additional safety data that may
be required for products containing agents considered immuno-
suppressive, which included MLV BVDV vaccines. The guidance,
however, does not specify what additional safety testing should
be conducted, and a current benchmark for changes expected with
BVDV vaccination has not been established. A better understanding
of the outcomes associated with BVDV vaccination as it relates to
lymphoid depletion would be beneficial. The various BVDV MLV
vaccines could modulate the immune response differently; there-
fore, as new vaccines are developed, understanding the impact of
BVDV MLV vaccines on the bovine immune system will be
necessary.
The objective of the current study was to compare immunolog-
ical changes after vaccination with current and previously avail-
able BVDV MLV vaccines in the US, and a ddGM vaccine which is
licensed in the EU, Mexico, Brazil and other countries around the
world. Comparison of the vaccines was based upon detection of
virus from nasal swabs and blood, CBCs to determine lymphocyte
numbers, flow cytometric analysis of PBMC subpopulations, devel-
opment of neutralizing antibodies, and lymphoid depletion in thy-
mus tissue.
2. Materials and methods
2.1. Experimental design
The study was designed as a randomized, controlled study. All
animals were handled in accordance with the Animal Welfare
Act Amendments (7 U.S. Code §2131 to §2156) and all study proce-
dures were reviewed and approved by the Institutional Animal
Care and Use Committee at the National Animal Disease Center
(ARS-2017-616).
Cattle enrolled in the study consisted of a sixty-four (n = 64)
colostrum-deprived Holstein bull calves approximately 3–4 weeks
of age at initiation of the study. The study was conducted in two
replicates consisting of thirty-two calves each assigned to eight
treatment groups with four calves in each respective group. Calves
were housed in biocontainment facilitates (ABSL2) separated by
group for the duration of the study. Prior to the start of the study,
all calves were tested to ensure they were negative for BVDV anti-
gen and antibodies as described previously [9,10].
2.2. Vaccine and virus administration
All cp vaccines were USDA licensed stock material approved for
commercial sale in the US and purchased through a single com-
mercial source with the exception of the ddGM vaccine that was
provided directly by Boehringer Ingelheim (BI) Animal Health
and the other ncp vaccine provided directly by Elanco Animal
Health. All vaccines were received in proper cold chain and were
cataloged and refrigerated. Vaccines were administered per manu-
facture label recommendation, and were administered within
15 min of preparation. Treatment group and vaccine details are
listed in Table 1 and described hereafter. Calves in group 1 received
monovalent ncp BVDV ddGM vaccine (Bovela, Boehringer Ingel-
heim Vetmedica, Inc. St. Joseph, MO). Calves in group 2 received
a 4-way multivalent MLV vaccine containing BoHV-1, BPI3V, BRSV,
and ncp BVDV-1 (Arsenal  4, Elanco Animal Health, Larchwood,
IA). Calves in group 3 received a 5-way multivalent MLV vaccine
containing bovine herpes virus-1 (BoHV-1), bovine parainfluenza-
3 virus (BPI3V), bovine respiratory syncytial virus (BRSV), and cp
BVDV-1 and 2 fractions (BoviShield GOLD 5, Zoetis, Parsippany,
NJ). Calves in group 4 received a 5-way multivalent MLV vaccine
containing BoHV-1, BPI3V, BRSV, and cp BVDV-1 and 2 fractions
(Titanium 5, Elanco Animal Health, Greenfield, IN). Calves in
group 5 received a 5-way multivalent MLV vaccine containing
BoHV-1, BPI3V, BRSV, and cp BVDV-1 and 2 fractions (Vista 5,
Merck Animal Health, Madison, NJ). Calves in group 6 received a
5-way multivalent adjuvanted MLV vaccine containing BoHV-1,
BPI3V, BRSV, and cp BVDV-1 and 2 fractions (Express 5, Boehrin-
ger Ingelheim Vetmedica, Inc., St. Joseph, MO). The adjuvant is a
sub-potent dose of Haemophilus Somnus in the Express 5 vaccine.
Calves in group 7 received 2 ml of sterile water by subcutaneous
(SQ) injection. Calves in group 8 were exposed to ncp BVDV-2 field
isolate RS886 via intranasal route (5 ml total/2.5 ml per nostril;
4.2  106 TCID50/ml) that has been previously characterized to
induce mild clinical signs consisting of pyrexia (>40 C) early in
the infection, moderate decrease in lymphocytes, viremia and viral
shedding. Characterization, propagation, and viral titer was deter-
mined as previously described [11].
Eight total treatment groups were utilized in the study that
included six different vaccines. While different BVDV strains were
present in each of the vaccines, the biotype (cp) of the BVDV iso-
lates were the same for three of the vaccines (cp vaccines; Groups
3, 4, and 5) and these three vaccines also lacked an adjuvant.
Distinguishing characteristics of the other three vaccines, were
presence of an adjuvant (adjuvanted vaccine; Group 6), ncp bio-
type (ncp vaccine; Group 4), and attenuation by double deleted
genetic modification (ddGM vaccine; Group 1). Groups 7 and 8
consisted of the control and ncp exposed BVDV field strain treat-
ments, respectively.
2.3. Sample collection
Sample time points included two baseline samples collected on
days 2 and 1 prior to administration of treatments for each
respective treatment group (Day 0). A rumen temperature probe
given as a bolus to record basal temperatures was administered
on day 2 of the study as previously described [12]. After admin-
istration of the respective material for each treatment group (Day
0), samples were collected on days 2, 4, 6, 9, 11, 13, and 16 post
administration of treatments. Samples collected at each time point
included; two nasal swabs for virus detection, blood samples for
detection of viremia, blood samples for complete blood counts
(CBCs), PBMC isolation for flow cytometric analysis and serum
for virus neutralization assays. Calves were euthanized by intra-
venous (IV) administration of sodium pentobarbital on day 17 for
collection of thymic tissue to be evaluated for lymphoid depletion.
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2.4. Virological assays
For virus detection, jugular blood samples were collected in
EDTA tubes, and buffy coat (BC) was separated by centrifugation
(25 min at 1200  g). The BC was collected and put through one
freeze/thaw cycle (-20 C/25 C). An aliquot of 140 mL of BC sample
was submitted to RNA extraction using QIAcube (Viral RNA kit)
according to the manufacture’s recommendations (Qiagen, Valen-
cia, CA). Extracted RNA was used for conventional reverse tran-
scriptase (RT) polymerase chain reaction (PCR) for DNA
sequencing to confirm that the virus detected was vaccine or virus
used for exposure. RT-PCR was performed using two published RT-
PCR assays that target the 5‘ untranslated region of the viral gen-
ome (5‘ UTR). The primer sets used were HCV90- 368 and 324–
326 with the reactions being performed as previously described
[13,14]. Sequences were edited and aligned using Geneious soft-
ware (Biomatters Inc, Newark, NJ), and comparison of generated
sequences to sequences of vaccine strains was performed using
Molecular Evolutionary Genetics Analysis software package 7
(MEGA7).
Upon collection, nasal swab (NS) samples were placed in micro-
tubes (1.5 ml) to which 1 ml of sterile PBS was added. NS samples
were stored at 20 C until analysis. After thawing, the NS samples
containing the swab were centrifuged for 2 min at 400  g to sep-
arate any debris from the swab itself. Similar to the BC sample, an
aliquot of 140 mL of the NS sample was submitted to RNA extrac-
tion, and RT-PCR was performed as previously described.
An aliquot of 140 mL of each vaccine and the RS886 virus used
for intranasal inoculation was subjected to RNA extraction using
QIAcube (Viral RNA kit) according to the manufacture’s recom-
mendations (Qiagen, Valencia, CA). Extracted RNA was subjected
to real-time quantitative PCR to quantify the total amount of BVDV
in each vaccine being administered to each calf. A 10-fold viral
dilution curve starting at 4.2  106 TCID50/ml using the RS886
virus used for intranasal inoculation, as a reference to provide a
relative quantification of total amount of BVDV RNA in the vac-
cines. The commercial real-time PCR assay detects a fragment of
the BVDV-1 and BVDV-2 50UTR (BVDV VetMax Gold, ThermoFisher
Scientific, Austin, TX). Samples were analyzed using QuantStudioTM
5 System (Applied Biosystems) with the respective software.
2.5. Serological assays
Blood was collected into serum separation tubes with gel and
clot activator (BD Vacutainer SST, Franklin Lakes, NJ), centrifuged
(25 min at 1200  g), and serum was collected and frozen at
80C until testing. A comparative virus neutralizing titer (VNT)
was determined using cytopathic isolates BVDV-1a-Singer and
BVDV-2a-296c as previously described [15]. Briefly, serum was
diluted in MEM from 1:2 to 1:256 in 96-well plates, and approxi-
mately 200 TCID of virus was added to each well. After a 1 h incu-
bation at 37 C with 5% CO2, 2  104 bovine turbinate (BTu) cells
were added to each well. After four days of incubation, dilution
endpoints were determined by observing cytopathic effect (CPE)
in the cell monolayer. Results were expressed as the reciprocal
(Log2 base) of the highest serum dilution able to inhibit the
appearance of CPE in cells. Serum samples were run in a 96-well
plate with five wells per dilution, and titers were calculated by
the Reed-Muench method.
2.6. Evaluation of peripheral lymphocytes
Calves were bled by jugular venipuncture, and blood was col-
lected in EDTA tubes (BD Vacutainer PPT tube, Franklin Lakes, NJ)
for submission to the Iowa State Veterinary Diagnostic Laboratory
for CBC determination. Specifically, the number of lymphocytes
was used to determine fluctuations in total circulating lympho-
cytes at each respective time point.
A third blood sample was collected in acid citrate dextrose
(ACD) (BD Vacutainer ACD Solution A, Franklin Lakes, NJ), and cen-
trifuged at 1200  g for 25 mins. Buffy coat layers were aspirated,
and the contaminating erythrocytes were removed by two rounds
of hypotonic lysis. Hypotonic lysis was performed by adding two
volumes of buffered water (lysis buffer) for approximately 30 secs
and then restoring with suspension to normal osmolality with one
volume triple strength PBS (restoring buffer). The resulting cell
suspensions were centrifuged at 400 g for 5 min to pellet the cells.
The cell pellets were washed with 5 ml of PBS to remove any resid-
ual lysis and restoring buffer and centrifuged again at 400 g for
2 min.
For flow cytometry labeling, cells were resuspended at approx-
imately 107 cells/ml in PBS and pelleted prior to resuspension and
incubation with fixable viability dye eFluor 450 or 455 UV to iden-
tify live/dead (LD) cells as described (eBioscience, San Diego, CA).
Cell suspensions were washed twice with stain buffer (BD Bio-
sciences, San Jose, CA) per manufacturer’s recommendations prior
to labeling. Cells were then resuspended in 100 lL of their respec-
tive primary monoclonal antibody mix for 30 min, followed by two
wash steps before being resuspended in their respective secondary
antibody mix for 30 min as previously described [16,17]. After two
wash cycles, cells were resuspended in 200 mL BDTM stabilizing fix-
ative (BD BioSciences, San Diego, CA) and kept in the dark at 4C
until flow cytometry analysis. Analysis was performed within
24 h of staining. The list of antibodies, panel configuration and
reagents used are summarized in Table 2.
2.7. Thymus evaluation
Formalin-fixed tissues were embedded in paraffin, cut in 5 mm
sections, stained with hematoxylin and eosin (HE) and examined
Table 1
Treatment groups and vaccine details.
Group Vaccine composition or type of treatment** Route* BVDV
biotype
Vaccine characteristics Company
1 monovalent BVDV IM ncp double deleted genetically
modified (ddGM)
Bovela, Boehringer Ingelheim Vetmedica, Inc.,
St. Joseph, MO
2 BoHV-1, BPI3V, BRSV, and BVDV-1 SQ ncp MLV Arsenal 4, Elanco Animal Health, Larchwood, IA
3 BoHV-1, BPI3V, BRSV**, and BVDV 1 and 2 SQ cp MLV BoviShield GOLD 5, Zoetis, Parsippany, NJ
4 BoHV-1, BPI3V, BRSV, and BVDV-1 and 2 SQ cp MLV Titanium 5, Elanco Animal Health, Greenfield, IN
5 BoHV-1, BPI3V, BRSV, and BVDV-1 and 2 SQ cp MLV Vista 5, Merck Animal Health, Madison, New Jersey
6 BoHV-1, BPI3V, BRSV, and BVDV-1 and 2 SQ cp MLV (with adjuvant) Express 5, Boehringer Ingelheim Vetmedica, Inc.,
St. Joseph, MO
7 control: 2 ml of sterile water SQ na na na
8 typical virulent BVDV-2 field isolate RS886 IN ncp na na
* IM = Intramuscular; SQ = Subcutaneous; IN = Intranasal.
** bovine herpes virus-1 (BoHV-1), bovine parainfluenza-3 virus (BPI3V), bovine respiratory syncytial virus (BRSV), and bovine viral diarrhea virus (BVDV).
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by light microscopy and morphometric analysis. Whole tissue
slides stained with HE were scanned using an Aperio ScanScope
XT workstation (Aperio Technology, Inc., Vista, CA) and analyzed
as previously described [6]. The color deconvolution (CD) algo-
rithm had four input threshold values that were modified based
on intensity of the hematoxylin stain quantified on the slides ana-
lyzed in this study. The positive color channel used was hema-
toxylin (1), and the threshold values modified from the standard
algorithm included: the black threshold (0, clear glass), weak pos-
itive threshold (185), medium positive threshold (105) and strong
positive threshold (105). The medium and strong threshold
parameters are the same only provide weak and strong positive
values and no intermediate medium values. Based on these param-
eters, detection of strong positive staining indicated cortex, and
detection of weak positive staining indicated medulla. The quan-
tification of the cortex:medulla ratio was based on the ratio of
strong positive to weak positive values.
2.8. Statistical analysis
All statistical analyses were performed using commercially
available statistical software (SAS v9.4, SAS Institute, Cary, NC)
and p-values of < 0.05 were considered significant. The frequency
of labeled cells for the respective PBMC populations (CD2+, CD3+,
CD4+, CD8+, cd+, and CD335+) was calculated and this value was
used for all subsequent calculations. Post-exposure daily values
for CBC lymphocyte data as well as PBMC populations relative to
baseline values were determined by calculating the percent change
from baseline levels for each calf on each respective day of the
study when samples were collected using the formula ((D-B)/
B X 100), where B is the baseline value (average the two baseline
samples, day 2 and 1) and D is the value for each respective
experimental day. The results from the calculation to determine
percent decline from baseline for each calf on each day were ana-
lyzed using the GLM procedure in SAS (SAS Inst., Cary, NC) with a
model that included the fixed effect of treatment at each experi-
mental day. When variables of interest were significant (P < 0.05)
for the fixed effect of treatment, contrasts among least square
(LS) means were evaluated for each experimental day to evaluate
differences between treatment groups. Figures were generated in
Microsoft Excel for significant variables and the standard error
of the mean was included using the standard error function in
Microsoft Excel.
Comparisons among LS means, indicated that no differences
were observed between the three cp vaccines lacking adjuvant
(Table 3). Therefore, for simplicity of presentation for the periph-
eral lymphocyte, CD4+ subpopulation, and thymus data for the vac-
cines containing the same BVDV cp biotype were combined into
one group identified as cp vaccines.
BVDV serum neutralizing titers were calculated as the recipro-
cal of serum antibody titers log2-transformed, which were then
back-transformed as geometric means for presentation of results.
3. Results
3.1. Clinical presentation
Calves were observed daily and no overt clinical disease was
observed in any of the study animals throughout the study. Tem-
perature was monitored over the course of the study as previously
described [12]. An increase in temperature was observed for calves
in the ncp exposed group (Group 8) on approximately day 6 of the
study and in the ncp vaccine calves (Group 2) on approximately
days 9 and 10. The increase in temperature was associated with
virus detection in the calves receiving the ncp vaccine and ncp
exposed calves.
3.2. BVDV-specific virus neutralizing antibodies
Antibody titers were determined prior to administration of any
treatments and 16 days post administration of treatments. No
detectable neutralizing antibody titers to BVDV were observed
prior to vaccination or exposure in all calves. A measurable neu-
tralizing BVDV antibody titer at day 16 was observed for all treat-
ment groups excluding the control animals which remained
negative for the duration of the study (Table 4). While antibody
titers observed at day 16 do not represent the complete immuno-
logical response to each respective antigen, these antibody titers
do support recognition by the immune system and response to
the respective BVDV antigens. These titers are reported to support
recognition of the immune system to BVDV, but the titers observed
on day 16 are not reflective of the titers that may be observed at a
later time point or should be correlated to immunity as these titers
do not reflect a complete response.
At 16 days post-vaccination, the BVDV-1 antibody titers for
adjuvanted vaccine calves (Group 6) were greater than the anti-
body titers observed for the ncp exposed calves (Group 8). In gen-
eral, at 16 days post-vaccination the BVDV-1 response was greater
for calves vaccinated with ncp vaccine (Group 2) and calves in cp
vaccine Group 5, but the BVDV-2 response was greater for cp vac-
cinated calves in Groups 3 and 4. In addition, the BVDV-2 response
was greater for ddGM vaccine and ncp exposed calves (Groups 1
and 7, respectively).
3.3. BVDV virus detection
For real-time PCR, samples were considered positive if the Ct
value was<30. Samples with Ct values>30 were considered suspect
or negative. Based on real-time PCR values, all vaccines used in the
study contained similar amounts of virus antigen, with the excep-
tion of the adjuvanted vaccine that had the least amount of virus as
detected by PCR (Table 4). The amount of live virus was not deter-
mined. While the real-time PCR results suggested less BVDV virus
in the adjuvanted vaccine, the level of neutralizing antibodies eli-
cited by this vaccine was greater than that elicited by other vacci-
Table 2
Summary of antibodies used for MP-FCM assays for PBMC comparisons.
Panel designation Primary antibody Clone Isotype Secondary antibody dye
Panel 1 CD3 MM1A IgG1 BV421
CD4 IL11A IgG2a APC
CD8a BAQ11A IgM PE
GD GB21A IgG2b APC/Cy7
CD45RO ILA116A IgG3 BUV395
CD31 MCA1097F IgG2a FITC (direct conjugation)
CD62L IgG1 PE/Cy7 (direct conjugation)
Panel 2 CD2 MUC2A IgG2a FITC
CD335 ASK1 IgG1 BV421
sIgM PIG45A IgG2b PE
CD14 CAM66A IgM APC
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nes in the study. Therefore, it is unknown if the adjuvant elicited a
greater response with less virus, or if the adjuvant or other compo-
nents interfered with PCR amplification. The manufacture of the cp
adjuvanted vaccine indicated that the vaccine includes a high titer
of BVDV, therefore, it would appear the lack of detection was asso-
ciated with PCR interference.
All study animals were negative for BVDV prior to the start of
the study, and all control calves remained negative throughout
the study. In the calves that received a vaccine, virus was only
detected from the ncp vaccine calves; no virus was detected from
any other vaccinated calves (Table 4). Virus was detected from
nasal swabs and PBMCs on day 9 in the ncp vaccinated calves.
Virus was also detected from nasal swabs and PBMCs in ncp
exposed calves on days 4, 6, 9, and 11.
3.4. Complete blood counts and PBMC subpopulation comparisons
As comparisons among LS means indicated that no differences
were observed between the three cp vaccines lacking adjuvant
(Table 3), presentation for the peripheral lymphocyte and CD4+
subpopulation for the three vaccines containing the cp BVDV bio-
type but lacking adjuvant were combined into one group identified
as cp vaccines.
The effect of treatment (P < 0.05; Table 3) was observed for two
of the peripheral leukocyte variables measured in the study. Per-
cent change from baseline was observed for the circulating lym-
phocytes on days 4, 6, and 9 and percent change from baseline
was also observed in the CD4+ subpopulation on days 4 and 6.
No statistically significant differences (P < 0.05) were observed
in percent decline of peripheral lymphocytes between the control
calves and calves that received the cp vaccines at any of the sample
time points (Table 3; Fig. 1). On days 4 and 6, a difference in per-
cent decline for peripheral lymphocytes was observed for calves
receiving the ncp, ddGM, and adjuvanted vaccines, as well as the
ncp exposed calves, as compared to the control and cp vaccinated
calves (Table 3; Fig. 1). On day 9, a difference in percent decline for
peripheral lymphocytes was observed for the ncp and ddGM vacci-
nes, and the ncp exposed calves, as compared to the control and cp
vaccinated calves (Table 3; Fig. 1). In general, calves administered
ncp BVDV either via vaccination or intranasal exposure had a
greater decrease in circulating peripheral lymphocytes as deter-
mined by percent decline from baseline compared to control calves
and calves receiving cp vaccines. While a difference in percent
decline for peripheral lymphocytes was observed for calves receiv-
ing the adjuvanted vaccine, the duration of decline was only
observed on days 4 and 6 and was not as prolonged as the calves
exposed to ncp BVDV.
No difference was observed in percent decline of CD4+ lympho-
cytes between the control calves and calves that received the cp
vaccines at any of the sample time points (Table 3; Fig. 2). On
day 4, a difference in percent decline for CD4+ lymphocytes was
observed for the ncp exposed calves, as compared to all other treat-
ment groups (Table 3; Fig. 2). On day 6, a difference in percent
decline for CD4+ lymphocytes was observed for ncp vaccine and
ncp exposed calves, as compared to the control and cp vaccinated
calves (Table 3; Fig. 2). While a slight decline in the CD4+ cells on
day 6 for the ddGM and adjuvanted vaccinated calves, the percent
decline was not as substantial as the decline seen with the ncp vac-
cine and ncp exposed calves. The percent decline for the CD4+ cells
on day 6 for the ddGM and adjuvanted vaccinated calves was
between that of the control and cp vaccinated calves and the ncp
vaccine and ncp exposed calves.
Table 3

















CBC Lymphocyte (Lym) 0.71 0.0001 0.0001 0.003 0.22 0.38 0.06



















Lym % decline day 4 ab cd cde e de bc e a
Lym % decline day 6 abc abc d d d a d ab
Lym % decline day 9 abc a d d d abcd d ab
Lym % decline day 16 a ab c c bc abc bc abc
CD4+ % decline day 4 b b b b b b b a
CD4+ % decline day 6 abc a c c abc abc c ab
Gross thymus bc a c c c c c ab
Histo thymus bc a cd d d D d ab
*Means with the same letter across each row are statistically similar (P < 0.05).
Table 4

















Group 8 ncp exposed
RT-qPCR Ct values for total
BVDV in each vaccine
22.2 22.0 22.3 18.5 18.6 30.0 UD* 17.7
Virus neutralization log(2) titer
BVDV type 1 (Singer) 0.4 1.8 0.0 0.0 0.7 5.4 0.0 0.5
BVDV type 2 (296c) 0.9 0.2 0.1 0.4 0.5 1.5 0.0 5.4
Virus isolation PBMC and
NS day 9
PBMC and NS days 4,
6, 9, and 11
* Undetermined.
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While there was not an effect of treatment (P < 0.05) observed
on day 16 for the percent change from baseline for the CD4+ pop-
ulation, a rebound effect after ncp exposure prompted a retrospec-
tive examination of the day 16 data. In short, the percent decline
from baseline at each respective time point should not be the only
variable of interest, and the rebound effect for each vaccination or
exposure should be considered. The percent decline is temporary,
and an emphasis on a greater rebound should be considered which
may be associated with a more robust memory response. The
subsequent rebound effect in the CD4+ population can be seen in
Figs. 2 and 3. There was no change from baseline in the control
calves, which is expected, but of the vaccines that induced a signif-
icant decline in the CD4+ population on days 4 and 6 post-
exposure, ddGM and the adjuvanted vaccines had a positive
rebound effect (Figs. 2 and 3). The ncp vaccine induced a significant
percent decline from baseline on days 4 and 6 (Table 3; Fig. 2) for
the CD4+ population, and by day 16 post-vaccination, the CD4+



























Fig. 1. Percent change from baseline values for peripheral circulating lymphocytes values as determined by complete blood counts. Data represents means from the

























Fig. 2. Percent change from baseline values for CD4+ cells as determined by multi-parameter flow cytometric analysis. Data represents means from the respective treatment
groups with the bars representing the standard error for each respective treatment group at each day post administration.
S.M. Falkenberg et al. Vaccine xxx (xxxx) xxx
6
is interesting given that the ncp exposed calves that had the great-
est percent decline in the CD4+ population on day 4 had returned to
just above baseline values on day 16 (Fig. 2). Calves administered
cp vaccines did not have a significant percent decline from baseline
in the CD4+ population after vaccination, however, a positive
increase from baseline on day 16 was observed, although it was
not as remarkable as the rebound in the ddGM and adjuvanted vac-
cinated calves (Fig. 3).
No statistical differences (P > 0.05) were observed between
treatment groups for percent change in the following PBMC sub-
populations; the monocyte (CD14+) cell population, cd T cells,
CD8+ T cells, B cells (sIgM+), CD2+ cells, natural killer cells
(CD335+), and CD31+ cells. Minimal changes may have been
observed (0.05 > P < 0.1), but no significant trends existed.
3.5. Thymus histopathology analysis
As comparisons among LS means indicated that no differences
were observed between the three cp vaccines lacking adjuvant
(Table 3), presentation for thymus measures for the three vaccines
containing the BVDV cp biotype but lacking adjuvant were com-
bined into one group identified as cp vaccines.
Histological observations of thymus depletion correlated with
reduced gross thymus weights. Three treatments resulted in signif-
icant changes (P < 0.05) in thymus histology and weight: ncp expo-
sure, ncp vaccine, and ddGM vaccine. There was a treatment effect
(P < 0.05; Table 3; Figs. 4 and 5) with the ncp vaccinated calves
having the greatest depletion of the thymus as measured by gross
thymus weight (reported as a ratio of thymus:kidney weight) and
depletion of the cortex:medulla ratio defined by strong:weak
straining of H&E stained slides (Figs. 4 and 5). The ncp exposed
calves had similar depletion of the thymus to that of the ncp vac-
cinated calves, but the depletion in the ddGM vaccine calves was
not as extensive as the ncp vaccine calves (Figs. 4 and 5). The
depletion pattern in the ddGM vaccine calves was between that
of the ncp exposed calves and the cp vaccine and control calves,
signifying that the depletion it was not as severe as in the ncp
exposed calves (Figs. 4 and 5). In general, both gross thymus
weight and histological observations were similar among treat-
ment groups, with the control and cp vaccine calves having the lar-
gest thymus with the greatest amount of strong positive staining
suggestive of less depletion of the cortex:medulla ratio.
4. Discussion
Colostrum-deprived calves were utilized in this study as this
model allows comparison of immune responses with fewer vari-
abilities than would be observed with conventional calves. The
immune systems of these calves may not be representative of
neonatal calves under standard management that have received
passive immunity via colostrum. However, as colostrum uptake
and/or quality may not always be ideal, this data provides insight
into responses under undesirable field/management conditions.
This study demonstrates differences in responses among the
commercial BVDV MLV vaccines utilized in this study. Some of
the vaccines also contained MLV strains of BoHV-1, BRSV, and
BPI-3. These viruses may have contributed to some of the effects
of the vaccines, but our goal was to evaluate the commercially
available vaccines as used in the field. One commonality between
all the vaccines used in this study was the inclusion of BVDV, but
the presentation of the BVDV within the vaccines was different;
cp or ncp BVDV, adjuvanted, or genetically modified. For this rea-
son, ncp exposed calves were included to compare the response
to commercially available vaccines containing BVDV to the
response generated by exposure to a field strain of virus. In addi-
tion, control calves administered a placebo, were used for
comparisons.
As expected, calves in the ncp vaccine and ncp exposed groups
had a greater decline in circulating peripheral lymphocytes and
CD4+ cells, in addition to viral shedding, viremia, and pyrexia, as
is characteristic of ncp BVDV infections [6]. While, the ddGM and
adjuvanted vaccinated calves had a decline in circulating periph-
Fig. 3. Percent change on day 16 from baseline values for CD4+ cells as determined by multi-parameter flow cytometric analysis. Data represents means from the respective
treatment groups.
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eral lymphocytes and CD4+ lymphocytes, calves in these groups did
not exhibit significant changes in temperature or shed virus. Fur-
thermore, the highest VN titers observed were in the adjuvanted
vaccine and ncp exposed calves, followed by the ddGM vaccine
and ncp vaccine calves. While neutralizing antibody titers were
observed in all vaccinated calves, higher antibody titers were asso-
ciated with a greater temporary decline in circulating peripheral
lymphocytes following exposure. Thus, the adjuvanted, ddGM,
and ncp vaccine and the ncp exposed calves, had both the highest
neutralizing antibody titers and the greatest temporary decline in
Fig. 4. Average ratio of adjusted gross thymus:kidney weight at necropsy on day 17. Data represents means from the respective treatment groups.
Fig. 5. Average ratio of strong:weak staining, representative of the cortex:medulla ratio of the thymus at necropsy on day 17. Data represents means from the respective
treatment groups.
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circulating lymphocytes. Furthermore, the comparatively higher
neutralizing antibody titers for the adjuvanted vaccine calves could
be due to the adjuvant contained in the vaccine, as none of the
other vaccines contained an adjuvant. This is also noteworthy as
the adjuvanted vaccine had the greatest PCR Ct value suggestive
of less total BVDV administered to the calves, but it is unknown
if components of the vaccine interfered with the results obtained
by PCR.
Peripheral circulating lymphocytes are constantly recirculating
in the blood after their reentry from lymphoid tissue to ensure a
full repertoire of antigen specificities is represented. Naïve lym-
phocytes are able to circulate through secondary lymphoid tissues
since they have not been exposed to antigen they recognize. After
entering secondary lymphoid tissues and exposure to antigen they
recognize, naïve lymphocytes can differentiate and contribute to
the adaptive immune response. This trafficking of lymphocytes to
lymphoid tissues is a coordinated and deliberate process and
may, in part, be responsible for the decline in peripheral circulating
lymphocytes observed after exposure to antigen. In addition to
lymphocytes trafficking to lymphoid tissues, viruses can also infect
lymphocytes leading to apoptosis which can also contribute to a
decline in circulating lymphocytes. Both trafficking of lymphocytes
and apoptosis can cause a temporary decrease in circulating lym-
phocytes, but determining if the decline in lymphocytes is associ-
ated with a contribution to a robust response or immune
suppression is important. Therefore, understanding the cause of
the decline in circulating lymphocytes or lymphocyte subpopula-
tions is important to determine if the decline in the lymphocyte
population will result in a beneficial or detrimental effect on the
immune response. Furthermore, the repopulation or rebound of
specific lymphocyte populations in the periphery should also be
considered as it relates to efficacy of antigen specific responses.
This can be observed in the rebound of CD4+ lymphocytes numbers
after antigen exposure in the current study, specifically in the
ddGM and adjuvanted vaccine calves.
Besides circulating lymphocytes, another site of lymphoid
depletion occurs in lymphoid organs such as the thymus. Depletion
of thymus tissue in BVDV infected animals correlates with viru-
lence of the virus [6,8,18]. While peripheral decline in circulating
lymphocytes has been previously reported to be associated with
depletion of the thymus [6], data from this study demonstrates
that these events are positively correlated. This is seen in the
response of calves to adjuvanted vaccine, as no difference was
observed in thymus gross weight or cortex:medulla ratio in this
group of calves as compared to control calves, despite the decline
in the peripheral blood lymphocyte population. However, signifi-
cant depletion of the thymus both grossly and histologically was
observed for the ncp vaccine and ncp exposed calves which also
had a significant decline in circulating lymphocytes. The ddGM
vaccine calves exhibited moderate signs of lymphoid depletion,
compared to ncp exposed and ncp vaccine, as all induced a decline
in circulating lymphocytes, but lymphoid depletion of the thymus
was less in the ddGM vaccine calves. The decline in the peripheral
blood lymphocyte population could be more of a consequence of
trafficking to the lymphoid tissue in adjuvanted vaccine calves as
demonstrated by the decline in the periphery, and the lack of thy-
mus depletion. A more detrimental immunological impact may be
observed in the ncp exposed and ncp vaccine calves as observed by
both peripheral lymphocyte decline and thymus depletion. It is
generally considered that the thymus does not regenerate, but
regeneration of the thymus has been suggested under the influence
of growth hormone [19–21], therefore, it is unknown to what
extent thymic depletion may be tolerated in animals that have
not reach maturity and are accumulating muscle mass.
Results from this study would suggest that different character-
istics of the BVDVwithin the vaccines used in the current study can
alter immunological measures. Therefore, selection of vaccines for
different classification of cattle such as stressed, immune compro-
mised, age, pregnancy status, etc., should consider the collective
data rather than focusing on one or two variables. These data high-
light the importance and the need for BVDV antigens to be pre-
sented in multiple platforms to provide the industry with vaccine
choices that can be tailored to the unique needs of each respective
cattle operation. Mounting an immune response comes at a phys-
iological cost. When the physiological cost of the protective
immune response is less than the physiological cost of contracting
the disease, there is a benefit to the animal. However, a more
robust immune response with a broader, longer response may
come with a higher physiological cost. The key is to effectively
manage or strategically induce responses when animals can
expend the physiological cost with minimal impact on general
health and productivity. Different life stages and environmental
stressors leave animals with varying levels of physiological
reserves that can be expended in order to mount an effective
immune response, therefore impacting long term physiological
and immunological consequences.
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